NeoGenomics Inc NEO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
NeoGenomics to Participate in Upcoming Investor Conferences
NeoGenomics Reports Third Quarter 2026 Results
NeoGenomics Expands Indica Labs Partnership to Scale AI-Powered Digital Pathology
NeoGenomics to Report Third Quarter 2026 Financial Results on October 28, 2026
NeoGenomics Announces Executive Leadership and Board of Directors Succession Plan
NeoGenomics to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
NeoGenomics Receives Medicare Coverage for RaDaR ST for Immunotherapy Treatment Response Monitoring
NeoGenomics to Pay $9.8 Million to Resolve Allegations of False Claims Act Violation
Trading Information
- Previous Close Price
- $16.96
- Day Range
- $16.75–17.67
- 52-Week Range
- $7.07–20.15
- Bid/Ask
- $16.83 / $17.21
- Shares Outstanding
- 129.39M
- Market Cap
- $2.18B
- Volume/Avg
- 957,231 / 2M
Key Statistics
- Price/Earnings (Normalized)
- 113.07
- Price/Sales
- 2.78
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Stock Style Box
- Small Growth
- Total Number of Employees
- 2,500
- Website
- https://www.neogenomics.com
Valuation
Metric | NEO |
|---|---|
Price/Earnings (Normalized) | 113.07 |
Price/Book Value | 2.73 |
Price/Sales | 2.78 |
Price/Cash Flow | 33.40 |
Price/Earnings
NEO
Financial Strength
Metric | NEO |
|---|---|
Quick Ratio | 3.04 |
Current Ratio | 3.53 |
Interest Coverage | −11.75 |
Quick Ratio
NEO
Profitability
Metric | NEO |
|---|---|
Return on Assets (Normalized) | 1.96% |
Return on Equity (Normalized) | 3.26% |
Return on Invested Capital (Normalized) | 2.01% |
Return on Assets
NEO
Diagnostics & Research Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Thermo Fisher Scientific Inc TMO | LOCK|<ly%@jrw | LOCK|^p@ | $266B | |||
| Danaher Corp DHR | LOCK|%nP>nSx# | LOCK|<< | $166B | |||
| IDEXX Laboratories Inc IDXX | LOCK|#KBvR%Jc | LOCK|KcD | $55B | |||
| Agilent Technologies Inc A | LOCK|XCMXqWk | LOCK|JHj | $50B | |||
| Waters Corp WAT | LOCK|!$wnwp | LOCK|f?X | $47B | |||
| IQVIA Holdings Inc IQV | LOCK|V$kqWZ | LOCK|rSr# | $45B | |||
| Mettler-Toledo International Inc MTD | LOCK|Bg%G><D | LOCK|S%kXF | $35B | |||
| Illumina Inc ILMN | LOCK|zTLhW^! | LOCK|?&&F | $32B | |||
| Labcorp Holdings Inc LH | LOCK|pL!v^tP | LOCK|$d&#$ | $30B | |||
| Quest Diagnostics Inc DGX | LOCK|Kf>cb? | LOCK|%hf&% | $28B |
United States